ArticleOncotarget2018

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.

Ling Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.